Trial · NCT07908823
ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation
NCT07908823, Not applicable, Not yet recruiting, Affiliated Hospital to Academy of Military Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation. Trials, record NCT07908823. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908823
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation
- NCT number
- NCT07908823
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
- Conditions
- Obesity & Overweight
- Interventions
- Endoscopic Radial Compression Gastroplasty (ERCG), Intensive Lifestyle Intervention (ILI)
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Total Body Weight Loss (%TBWL) at Week 12 | Weeks 12 after randomization | Percentage of total body weight loss (%TBWL) at Week 12 relative to randomization, calculated as \[(body weight at randomization- Week 12 body weight) / body weight at randomization\] × 100%. |
| Secondary | Percentage of Total Body Weight Loss (%TBWL) at Week 24 and 52 | Weeks 24 and 52 after randomization | Percentage of total body weight loss (%TBWL) at Week 24 and 52 relative to randomization, calculated as \[(body weight at randomization- Week 24 or 52 body weight) / body weight at randomization\] × 100%. |
| Secondary | Body Mass Index (BMI) at Week 12, 24 and 52 | Weeks 12, 24, and 52 after randomization | Body mass index will be calculated as body weight in kilograms divided by the square of height in meters and reported in kg/m² at each specified follow-up visit. |
| Secondary | Waist Circumference at Weeks 12, 24, and 52 | Weeks 12, 24, and 52 after randomization | Waist circumference will be measured in centimeters using a measuring tape around the abdomen at the level of the umbilicus at each specified follow-up visit. |
| Secondary | Fasting Glucose, HbA1c and Lipid Panel at Week 12, 24 and 52 | Weeks 12, 24, and 52 after randomization | Fasting glucose measures the level of blood glucose on an empty stomach; the HbA1c test provides a measure of average blood sugar levels over a three-month period; lipid panel includes three measurements of cholesterol levels and a measurement of triglycerides. |
| Secondary | Impact of Weight on Quality of Life-Lite (IWQOL-Lite) Total Score at Weeks 12, 24, and 52 | Weeks 12, 24, and 52 after randomization | Weight-related quality of life will be assessed using the 31-item Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire. The total score will be calculated according to the instrument's scoring instructions and transformed to a scale ranging from 0 to 100, with higher scores indicating better weight-related quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908823
GET https://conductscience.org/api/trials/v1/NCT07908823/registered